Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6706 to 6720 of 7691 results

  1. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued [GID-TA10045]

  2. Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]

    Discontinued [GID-TA10321]

  3. Alzheimer's disease (early) - gantenerumab [ID6142]

    In development [GID-TA11269] Expected publication date: TBC

  4. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued [GID-TA10277]

  5. Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545]

    Discontinued [GID-TAG444]

  6. Faller's clinics for the assessment and prevention of falls [ID103]

    Discontinued [GID-TAG375]

  7. Pembrolizumab for previously treated multiple myeloma (ID1139)

    Discontinued [GID-TA10193]

  8. Dasatinib for the treatment of acute lymphoblastic leukaemia [ID386]

    Discontinued [GID-TAG399]

  9. Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

    Discontinued [GID-TA10353]

  10. Contusugene ladenovec for the treatment of recurrent unresectable squamous cell carcinoma of the head and neck [ID76]

    Discontinued [GID-TAG407]

  11. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued [GID-TA10318]

  12. Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071]

    Discontinued [GID-TA10110]

  13. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued [GID-TAG360]

  14. Multiple myeloma - bortezomib (consolidation therapy) [ID529]

    Discontinued [GID-TAG320]